Drug Profile
Research programme: Escherichia coli vaccine - Baxter International/Roche
Latest Information Update: 20 Oct 2021
Price :
$50
*
At a glance
- Originator Baxter International
- Developer Baxter International; Roche
- Class Escherichia coli vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Urinary tract infections
Most Recent Events
- 26 Jun 2007 BioVeris Corporation has been acquired and merged into Roche
- 12 Oct 2000 New profile
- 12 Oct 2000 Preclinical development for Urinary tract infections in USA (Unknown route)